Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

UK trials new breathing aid developed by Mercedes Formula One

Published 30/03/2020, 06:55
© Reuters.

LONDON (Reuters) - A new version of a breathing aid that can help coronavirus patients has been developed in less a week by a team involving Mercedes Formula One, and is being trialled at London hospitals.

Continuous Positive Airway Pressure (CPAP) devices have been used in China and Italy to deliver air and oxygen under pressure to patients' lungs to help them breathe without the need for them to go on a ventilator, a more invasive process.

The new CPAP has already been approved by the relevant regulator and now 100 of the machines will be delivered to University College London Hospital for trials, before being rolled out to other hospitals.

Reports from Italy indicate that approximately 50% of patients given CPAP have avoided the need for invasive mechanical ventilation, which involves patients being sedated, freeing up ventilators for those more in need.

"These devices will help to save lives by ensuring that ventilators, a limited resource, are used only for the most severely ill," UCLH critical care consultant Professor Mervyn Singer said in a statement on Monday.

"We hope they will make a real difference to hospitals across the UK by reducing demand on intensive care staff and beds, as well as helping patients recover without the need for more invasive ventilation."

The new breathing aid was developed by engineers and clinicians at UCLH teaming up with Mercedes-AMG High Performance Powertrains who worked at UCL's MechSpace hub to reverse engineer a device that can be produced quickly.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Asked about the risk to healthcare workers of using CPAPs as contaminated droplets can escape from the device, Professor Rebecca Shipley, Director of UCL Institute of Healthcare Engineering, told the BBC, that the risks were very low if those workers wore appropriate personal protective equipment.

She also said that the new device could be scaled up very quickly.

"Mercedes can make 1,000 a day within a week, and if the tests go well they can be in the NHS by the end of this week," Shipley told BBC radio.

Development of the new device took fewer than 100 hours from initial meeting to production of the first one. The team working on it also includes Oxford Optronix, a small company that will manufacture the oxygen monitors for the CPAP devices.

Britain announced separately on Monday that it has placed an order for 10,000 ventilators to be made by a consortium of companies including Ford, Airbus and Rolls-Royce (LON:RR) as part of efforts to fight the coronavirus, an industry source told Reuters.

Latest comments

Superb- well done Mercedes
Brialliant , this is the sort of innovation we want.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.